NCT05886244View on ClinicalTrials.gov

Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in China

PHASE3CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

July 5, 2023

Primary Completion Date

April 14, 2025

Study Completion Date

April 14, 2025

Conditions
Paroxysmal Nocturnal Hemoglobinuria
Interventions
DRUG

Eculizumab

Participants will receive 600 milligrams (mg) once a week on Day 1, 8, 15, and 22 followed by 900 mg every 2 weeks from Day 29 to Day 435.

Trial Locations (7)

200040

Research Site, Shanghai

226001

Research Site, Nantong

300020

Research Site, Tianjin

300050

Research Site, Tianjin

310003

Research Site, Hangzhou

430022

Research Site, Wuhan

CN-100730

Research Site, Beijing

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Alexion Pharmaceuticals, Inc.

INDUSTRY